Lyra Therapeutics, Inc. (LYRA)

4.0500 -0.5800 (-12.53%) As of 01:50PM EDT. Market open.

Lyra Therapeutics, Inc.

480 Arsenal Way
Watertown, MA 02472
United States
617 393 4600
https://lyratherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 88

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Harlan W. Waksal M.D.	Executive Chairman	210.06k	N/A	1953
Dr. Maria Palasis Ph.D.	CEO, President & Director	942.7k	N/A	1965
Dr. John E. Bishop Ph.D.	Chief Technology Officer	662.9k	N/A	1962
Dr. Carmichael S. Roberts Jr., Ph.D.	Co-Founder	N/A	N/A	1969
Mr. Jason Cavalier	CFO, Treasurer & Secretary	464.11k	N/A	1973
Mr. Ray Knox	Vice President of Operations	N/A	N/A	N/A
Ms. Ellen Cavaleri	Senior Vice President of Investor Relations & Communications	N/A	N/A	N/A
Mr. Ronan P. O'Brien J.D.	Chief Legal Officer	N/A	N/A	1973
Ms. Corinne Noyes	Senior Vice President of Commercial Strategy & Market Development	426.73k	N/A	1968
Ms. Vineeta Belanger Ph.D.	Senior Vice President of Clinical Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Corporate governance

Lyra Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.